ARTL — Artelo Biosciences Share Price
0.000.00%
Last trade - 00:00- $3.41m
- $1.07m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.19 | ||
| Price to Tang. Book | 4.17 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -345.45% | ||
| Return on Equity | -134.52% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutics that modulate lipid-signaling pathways. The Company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 2nd, 2011
- Public Since
- October 13th, 2015
- No. of Shareholders
- 165
- No. of Employees
- 6
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 3,281,032
- Address
- 505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, 92075
- Web
- https://artelobio.com/
- Phone
- +1 8589257049
- Auditors
- Malone Bailey, LLP
Upcoming Events for ARTL
Q2 2025 Artelo Biosciences Inc Earnings Release
Similar to ARTL
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Artelo Biosciences share price?
As of Today at 07:21 UTC, shares in Artelo Biosciences are trading at $1.04. This share price information is delayed by 15 minutes.
How has the Artelo Biosciences share price performed this year?
Shares in Artelo Biosciences last closed at $1.04 and the price had moved by -22.39% over the past 365 days. In terms of relative price strength the Artelo Biosciences share price has underperformed the S&P500 Index by -28.36% over the past year.
What are the analyst and broker recommendations for Artelo Biosciences?
The overall consensus recommendation for Artelo Biosciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Artelo Biosciences dividend yield?
Artelo Biosciences does not currently pay a dividend.
Does Artelo Biosciences pay a dividend?
Artelo Biosciences does not currently pay a dividend.
When does Artelo Biosciences next pay dividends?
Artelo Biosciences does not currently pay a dividend.
How do I buy Artelo Biosciences shares?
To buy shares in Artelo Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Artelo Biosciences?
As of the previous close price of $1.04, shares in Artelo Biosciences had a market capitalisation of $3.41m.
Where are Artelo Biosciences shares listed?
Here are the trading details for Artelo Biosciences:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ARTL
What kind of share is Artelo Biosciences?
Based on an overall assessment of its quality, value and momentum Artelo Biosciences is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Artelo Biosciences share price forecast for 2025?
The analyst consensus target price for shares in Artelo Biosciences is $5.50. That is 428.85% above the last closing price of $1.04.
Analysts covering Artelo Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$1.16 for the next financial year.
Find out moreWhat is the trend in the Artelo Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Artelo Biosciences. Over the past six months, its share price has underperformed the S&P500 Index by -6.31%.
As of the last closing price of $1.04, shares in Artelo Biosciences were trading -9.11% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Artelo Biosciences PE Ratio?
The Artelo Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.04.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Artelo Biosciences?
We do not have data on Artelo Biosciences' directors